ICLR vs. VTRS: ICON vs. Viatris Stock Comparison
How do ICON (ICLR) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
ICON (ICLR) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while VTRS is classified in Pharmaceuticals.
| Profile Item | ICLR | VTRS |
|---|---|---|
| Name | ICON plc | Viatris Inc. |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 15.34 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 15, 1998 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| Total Return (1Y) | 30.55% | 108.98% |
| Total Return (3Y, Annualized) | -6.05% | 36.75% |
| Total Return (5Y, Annualized) | -5.40% | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 68.62% | 32.53% |
| Beta (5Y) | 1.17 | 0.86 |
| Max Drawdown (5Y) | -76.87% | -45.69% |
| Avg. Volume (3M) | 943.50K | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.38 | 3.22 |
| Sortino Ratio (1Y) | 0.52 | 5.63 |
Profitability
ROE (TTM)
Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both ICON (ICLR) at 10.73% and Viatris (VTRS) at 13.85% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| ROE (TTM) | 4.70% | -4.21% |
| ROA (TTM) | 0.85% | 2.91% |
| Net Margin (TTM) | 5.26% | -4.13% |
| Operating Margin (TTM) | 10.73% | 13.85% |
| Gross Margin (TTM) | 23.44% | 41.13% |
Growth
Revenue Growth
ICON (ICLR) at 0.76% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.
Growth Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| Revenue Growth (YoY) | 0.76% | -2.98% |
| Revenue Growth (3Y CAGR) | 2.15% | -4.20% |
| EPS Growth (YoY) | -71.56% | -- |
| EPS Growth (3Y CAGR) | -23.82% | -- |
Financial Strength
Current Ratio (MRQ)
Both ICON (ICLR) at 1.32 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 1.55 |
| Debt / Equity (MRQ) | 0.38 | 0.99 |
| Net Debt / EBITDA | 5.55 | 2.64 |
Dividends
Dividend Yield (TTM)
ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; ICON (ICLR) pays no dividend (payout 0.00%).
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.53% |
| Dividend Payout Ratio (TTM) | 0.00% | 960.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Both ICON (ICLR) at 1.86 and Viatris (VTRS) at 1.55 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Relative to net asset value, both ICON (ICLR) at 1.68 and Viatris (VTRS) at 1.67 look inexpensive, sitting in the lower P/B ratio quartile of their industries.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | ICLR | VTRS |
|---|---|---|
| P/E Ratio (TTM) | 81.90 | -- |
| P/S Ratio (TTM) | 1.86 | 1.55 |
| P/B Ratio (MRQ) | 1.68 | 1.67 |
| Free Cash Flow Yield (TTM) | 3.51% | 13.84% |